Investment Rating - The report maintains a "Hold" rating for the pharmaceutical sector [6] Core Insights - The pharmaceutical sector experienced a week-on-week decline of 0.68%, underperforming both the ChiNext Index and the CSI 300 Index, ranking 17th among all industries [2][36] - The report emphasizes a positive outlook for innovation, international expansion, and turnaround opportunities in the pharmaceutical industry, with a focus on BD 2.0, small nucleic acids, and supply chain [3][4] Summary by Sections 1. National Essential Drug List Adjustment Analysis - The adjustment of the National Essential Drug List is urgent as the current version has not been updated since 2018, leading to a disconnect with current clinical needs [14] - The new adjustments will focus on three main areas: addressing gaps in disease coverage, solidifying the integration of centralized procurement and national negotiation results, and enhancing the evidence-based standards for traditional Chinese medicine [5][14] - Potential beneficiaries from the adjustments include companies like Panlong Pharmaceutical, Guizhou Sanli, and Yiling Pharmaceutical, particularly in pediatrics, orthopedics, and cardiovascular fields [5][28] 2. JP Morgan Conference Overview - The 44th JP Morgan Health Conference highlighted strategic developments from major global pharmaceutical companies, showcasing their core pipeline progress and key clinical milestones for 2026 [33] - Companies such as Pfizer, Merck, and Eli Lilly presented their focus on advancing clinical trials and launching new products in various therapeutic areas [34][35] 3. Pharmaceutical Market Review and Hotspot Tracking - The pharmaceutical sector's performance from January 12 to January 16 showed a decrease of 0.68%, with a total trading volume of 916.83 billion yuan, accounting for 5.35% of the total market [2][36] - The report notes that the sector has shown a year-to-date increase of 7.08%, outperforming both the CSI 300 and ChiNext indices [36]

证券之星消息，1月21日，生物经济（970038）指数报收于2249.37点，涨0.3%，成交272.77亿元，换手 率2.27%。当日该指数成份股中，上涨的有28家，迪安诊断以5.59%的涨幅领涨，下跌的有22家，康弘药 业以1.78%的跌幅领跌。 生物经济（970038）指数十大成份股详情如下： | 代码 | 名称 | 主力净流入(元) | 主力净占比 游资净流入 (元) | | 游资净占比 散户净流入 (元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | | 000021 | 深科技 | 1.87亿 ﮯ | 3.06% | -9441.13万 | -1.55% | -9272.83万 | -1.52% | | 300142 | 沃森生物 | 6444.78万 | 8.62% | -3115.26万 | -4.16% | -3329.52万 | -4.45% | | 000930 | 中粮科技 | 5427.62万 | 9.84% | 491.65万 | 4 0.89% | -5919.27万 | -10.73% | | 002 ...

Summary of Hangzhou Tigermed Consulting Conference Call Industry Overview - The conference call focused on China's clinical Contract Research Organization (CRO) industry, highlighting significant trends and developments from 2019 to 2025 [2][3]. Key Points 1. **CRO Outsourcing**: Approximately 50% of clinical trials conducted in China were outsourced to CROs during the period from 2019 to 2025 [3]. 2. **Market Growth Rates**: The market's compound annual growth rate (CAGR) slowed from 25% during the COVID-19 period (2020-2022) to 4% in the post-COVID period (2023-2024). However, it is projected to accelerate to 13% from 2025 to 2028 according to Frost & Sullivan and the Human Genetic Resources Administration [3]. 3. **CRO Overcapacity**: The number of Chinese CROs decreased from 500 in 2024 to 480 in 2025, while the average number of annual trials conducted per CRO increased from 35.6 to 42.9 [3]. 4. **Clinical Trial Approvals**: In 2025, the number of clinical trial approvals (INDs) and Phase 1 trial starts in China rose by 19% and 13%, reaching 2,703 and 1,168 respectively [4]. 5. **Outlicensing Deals**: China executed 178 novel drug outlicensing deals to the US and Europe from 2024 to 2025, accounting for 14% of the world's total, an increase from 85 deals (9% of the total) from 2022 to 2023 [4]. 6. **Biotech Funding**: Chinese biotech companies raised $5.2 billion from private equity and venture capital in 2025, up from $4.2 billion in 2024. Total upfront payments from outlicensing also increased from $4.4 billion to $7.5 billion [4]. 7. **Global Drug Pipeline Contribution**: China now contributes approximately 30% to the global innovative drug pipeline [5]. 8. **Patient Enrollment Efficiency**: The average time to enroll a patient in China for an oncology trial is 60 days, compared to the global median of 150 days [5]. 9. **New Orders for Tigermed**: New orders for Tigermed increased across various customer types from January to November 2025, with biotech companies and multinational corporations (MNCs) being the largest contributors at 38% and 25% respectively. MNCs are responsible for 25-30% of Phase 3 trials in China [5]. 10. **Trial Pricing Trends**: Prices for Phase 1 and 2 trials reached their lowest point in 2024 and began to rise in 2025, aligning with levels similar to 2023 but remaining significantly below the peak levels seen during COVID-19 in 2022 [6]. Financial Metrics for Hangzhou Tigermed Consulting - **Stock Rating**: Overweight - **Price Target**: RMB 81.00, representing a 35% upside from the current price of RMB 60.03 as of January 20, 2026 [7]. - **Market Capitalization**: RMB 52.383 billion [7]. - **Revenue Projections**: Expected revenue growth from RMB 6.603 billion in 2024 to RMB 8.458 billion by 2027 [7]. - **Earnings Per Share (EPS)**: Projected EPS growth from RMB 0.46 in 2024 to RMB 1.85 in 2027 [7]. - **Return on Equity (ROE)**: Expected to increase from 1.9% in 2024 to 7.2% in 2027 [7]. Risks Identified - **Upside Risks**: Faster growth in clinical R&D outsourcing, accelerated recovery of domestic demand, and new collaboration deals [13]. - **Downside Risks**: Slower-than-expected recovery in clinical CRO demand, rising pricing pressure, geopolitical risks, and potential impairment of goodwill and intangible assets [13]. This summary encapsulates the critical insights from the conference call regarding the clinical CRO industry in China and the financial outlook for Hangzhou Tigermed Consulting.

Core Insights - The CRO industry in China is experiencing significant growth, with the market size expected to expand from 90 billion yuan in 2021 to 126 billion yuan by 2024, reflecting a compound annual growth rate (CAGR) of 28%, which is substantially higher than the global average of 10% [13][26] - The industry is characterized by a clear competitive landscape, with WuXi AppTec as the dominant player, achieving revenue exceeding 20 billion yuan, while other key players include Kanglong Chemical, Tigermed, and Kelun Pharmaceutical [17][20] Industry Overview - Contract Research Organizations (CROs) are specialized entities that undertake drug development responsibilities on behalf of pharmaceutical companies, helping to reduce costs and risks while ensuring compliance [1] - The CRO industry is divided into preclinical and clinical segments, with preclinical CROs focusing on drug discovery and safety evaluations, while clinical CROs handle clinical trials and data management [1] Industry Development History - The CRO industry in China began in 1996 with the establishment of the first joint venture, and has evolved from a lack of formal organizations to a competitive landscape dominated by local leaders [9] - The industry has undergone significant changes, including the implementation of Good Clinical Practice (GCP) in 2003 and the introduction of the Marketing Authorization Holder (MAH) system, which has facilitated the growth of CRO services [11] Market Demand and Growth - The number of New Drug Applications (NDA) in China has been increasing, from 210 in 2021 to an expected 320 by 2024, driving demand for CRO services [14] - The global CRO market is projected to grow from 71 billion USD in 2021 to 90 billion USD by 2024, driven by increased healthcare demands due to aging populations and the COVID-19 pandemic [13] Competitive Landscape - The competitive structure of the Chinese CRO industry is categorized into three tiers, with WuXi AppTec leading the first tier, followed by Kanglong Chemical and Tigermed in the second tier, and smaller firms in the third tier [17] - Most companies are diversifying their services to include both CRO and CDMO (Contract Development and Manufacturing Organization) capabilities, enhancing operational efficiency [20] Regional Market Dynamics - The Yangtze River Delta region dominates the CRO market in China, accounting for approximately 43% of the market share, followed by the Beijing-Tianjin-Hebei region at 23% and the Pearl River Delta at 19% [23] Future Outlook - The Chinese CRO market is expected to continue its growth trajectory, potentially exceeding 144 billion yuan by 2028, supported by favorable policies and increasing demand for innovative therapies [26] - Despite challenges such as rising compliance costs and market saturation, the overall outlook remains positive, with expectations of sustained double-digit growth over the next five years [26]

Industry Overview - The Chinese clinical CRO industry is entering a recovery and stable growth phase, transitioning from an offshore outsourcing model to a global contributor of innovative assets over the past decade [2][13] - The industry experienced a growth phase from 2017-2019 and a rapid development period from 2020-2022, with a forecasted compound annual growth rate (CAGR) of over 12% from 2025 to 2028, expecting to exceed 75 billion RMB by 2028 [2][13] - As of December 2025, the average number of clinical trial projects undertaken by each clinical CRO in China increased by 20.6% year-on-year, reaching 42.9 projects, narrowing the gap with the U.S. [5][16] Investment Trends - The investment from multinational pharmaceutical companies in China's clinical trials remains stable, with 25%-30% of Phase III innovative drug trials initiated by these companies over the past eight years [6][17] - Local pharmaceutical companies are also actively investing in innovative drug clinical research, contributing 15%-20% of Phase III trials in China during the same period [6][17] - The financing channels for Chinese innovative drugs have diversified, with a significant increase in licensing and mergers and acquisitions (M&A) transactions, totaling 178 deals in 2024-2025 [9][20] Company Highlights - Tigermed has ranked first in market share in China's clinical CRO sector for several years, with a compound annual growth rate of 14.8% in new orders from 2019 to 2024, surpassing the market's growth rate of 12.5% [11][23] - The average price of domestic clinical trial services is stabilizing after fluctuations in 2022-2023, indicating strong business continuity and resilience [11][23] - In 2025, Tigermed aims for sustainable development, achieving an AAA rating in MSCI ESG, and enhancing its service capabilities through the acquisition of CRO company Micron [11][23] - The company is investing in AI applications and platforms, launching an AI medical translation platform and an AI medical writing platform in 2025 [11][23]

Economic Overview - The GDP growth for Q4 2025 is reported at 4.5%, matching expectations but down from 4.8% in the previous quarter. December retail sales growth is at 0.9%, below the expected 1.5% and previous 1.3% [12][12] - Fixed asset investment shows a cumulative year-on-year decline of 3.8%, worse than the expected decline of 2.4% and previous 2.6%. Real estate development investment has a cumulative decline of 17.2% compared to the previous 15.9% [12][12] - Industrial value-added growth for December is reported at 5.2%, exceeding the expected 4.9% and previous 4.8% [12][12] Key Changes in Economic Structure - Three significant changes are identified: improvement in service consumption, easing of the "crowding out effect" from debt reduction, and recovery in new economic sectors [12][12] - The shift in consumption policies from goods to services is noted, with service retail growth increasing while traditional retail indicators decline [12][12] - Investment slowdown is attributed to intensified corporate debt repayment policies, which ultimately benefit cash flow recovery for companies [12][12] Sector Performance - The electric grid equipment sector shows a significant increase of 60.88% over the past six months, with a daily increase of 7.01% [1] - The digital media sector has seen a decline of 4.34% yesterday, with a 21.93% increase over the past month [1] - The hotel and catering industry has increased by 3.87% yesterday and 20.46% over the past six months, indicating resilience in service consumption [1] Investment Opportunities - The report highlights potential investment opportunities in sectors benefiting from service consumption recovery and easing debt repayment pressures [12][12] - Companies in the PCB drilling needle industry are noted for their growth potential, driven by increasing demand in emerging markets [20][20] - The report suggests focusing on companies with strong cash flow recovery and those positioned in high-growth sectors such as healthcare and technology [12][12][20]

Investment Rating - The report maintains an "Outperform" rating for several companies, including Jiangsu Heng Rui Medicine, Hansoh Pharmaceutical Group, 3SBio, Sichuan Kelun Pharmaceutical, and Jiangsu Nhwa Pharmaceutical [6][7]. Core Insights - The annual J.P. Morgan Healthcare Conference concluded successfully, with positive information from global pharmaceutical companies, including new pipeline disclosures and major deals. The report highlights the high prosperity in the innovative drug sector and recommends continuous investment in innovative drugs and the industry chain [25][26]. - The A-Shares pharmaceutical sector underperformed the market in the third week of January 2026, with the Shanghai Composite Index falling by 0.4% and the SW Pharmaceutical and Biological sector declining by 0.7% [8][27]. - The Hong Kong stock pharmaceutical sector performed in line with the market, while the U.S. pharmaceutical sector underperformed. The Hang Seng Healthcare index increased by 2.4%, and the S&P 500 Healthcare Select Sector decreased by 1.1% [28]. Summary by Sections Section 1: Continuous Recommendation of Innovative Drugs and Industry Chain - The report emphasizes the high prosperity of innovative drugs and maintains overweight ratings for key pharmaceutical companies. It also recommends Biopharma/Biotech companies with promising pipelines and volume increases, as well as CXO and upstream companies benefiting from innovation [6][25]. Section 2: A-Shares Pharmaceutical Sector Performance - In the third week of January 2026, the A-Shares pharmaceutical sector's performance was ranked 17th among Shenwan primary industries, with a decline of 0.7%. The medical service sub-sector showed a positive performance of +3.3% [8][12][27]. Section 3: Hong Kong and U.S. Pharmaceutical Sector Performance - The Hong Kong pharmaceutical sector performed similarly to the market, while the U.S. sector underperformed. Notable gainers in the U.S. included MODERNA (+22%) and QUEST DIAGNOSTICS (+9%), while major decliners included BIOGEN (-12%) and BOSTON SCIENTIFIC (-10%) [28].

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology industry [2]. Core Insights - The report highlights the ongoing performance of the pharmaceutical sector, with a focus on the upcoming annual earnings forecasts and the potential for exceeding expectations. The sector has shown a return of 7.08% since the beginning of 2026, outperforming the CSI 300 index by 4.88% [8][12]. - Key catalysts in the industry include significant partnerships and acquisitions, such as AbbVie’s $6.5 billion upfront payment for RC148 and a $1 billion collaboration between Eli Lilly and NVIDIA to accelerate AI drug development [4][10]. - The report emphasizes the importance of innovative drug chains and the AI+ theme, suggesting that these areas will continue to attract investment and yield positive results [4][5]. Summary by Sections Industry Overview - The pharmaceutical sector's total market capitalization is approximately 74,744.70 billion yuan, with a circulating market value of 68,522.64 billion yuan [2]. - The report notes that the pharmaceutical sector is currently valued at 23.4 times PE based on 2026 earnings forecasts, which is a premium of 13.7% compared to the overall A-share market [15]. Market Dynamics - The report indicates that the pharmaceutical sector has experienced a mixed performance, with medical services up by 3.29% while other segments like medical devices and traditional Chinese medicine have seen declines [8][12]. - The report also mentions that the market is transitioning to a more rational and steady growth phase, moving away from the initial volatility seen at the start of the year [4]. Key Company Performances - Notable companies such as WuXi Biologics, Sangamo Therapeutics, and Tigermed have been highlighted for their strong performance, with WuXi Biologics showing a significant increase of 26.53% in January [24]. - The report suggests continued monitoring of companies involved in AI and small nucleic acid technologies, as they are expected to lead future growth in the sector [5][9]. Investment Recommendations - The report recommends focusing on companies that are well-positioned within the innovative drug chain and AI+ sectors, as these are anticipated to provide substantial returns [4][5]. - Specific stocks recommended include WuXi Biologics, Sangamo Therapeutics, and Tigermed, which have shown promising growth trajectories [24].

Market Overview - The Hong Kong stock market opened lower on January 19, with the Hang Seng Index at 26,641.60 points, down 203.36 points, a decline of 0.76% [1] - The Hang Seng Tech Index opened at 5,777.07 points, down 45.11 points, a decrease of 0.77% [4] Airline Sector Performance - Airline stocks showed resilience, with China Eastern Airlines (HK00670) rising over 6%, and both China Southern Airlines (HK01055) and Air China (HK00753) increasing by more than 2% [3] - China Eastern Airlines reported a 4.93% year-on-year increase in passenger capacity for December 2025, with passenger turnover up 7.61% and a seat load factor of 85.65%, up 2.14 percentage points [6] - China Southern Airlines announced an 11.89% year-on-year increase in passenger capacity for December 2025, with passenger turnover up 11.20% and a seat load factor of 84.05%, down 0.53 percentage points [7] - Air China reported a 4.0% year-on-year increase in passenger capacity for December 2025, with passenger turnover up 10.0% and a seat load factor of 82.2%, up 4.5 percentage points [7] Other Sector Movements - The technology sector saw widespread declines, with Bilibili dropping over 4%, Alibaba and Kuaishou down over 2%, and Xiaomi and Meituan down over 1% [7] - The metals sector was active, with Zijin Mining opening over 1% higher [7] - The lithium battery sector experienced mostly gains, with BYD rising over 1% [7] - The domestic real estate sector faced declines, with Country Garden falling over 10% [7] - The biopharmaceutical sector opened lower, with Tigermed down over 2% [7] Economic Outlook - According to Galaxy Securities, the U.S. CPI for December 2025 rose 2.7% year-on-year, with core CPI up 2.6%, both in line with previous values [8] - The U.S. PPI for November increased by 3%, exceeding the forecast of 2.7% [8] - Initial jobless claims in the U.S. decreased by 9,000 to 198,000, significantly below the market expectation of 215,000, marking the lowest level since November of the previous year [8] - China's foreign trade in 2025 reached 45.47 trillion yuan, a year-on-year growth of 3.8%, marking nine consecutive years of growth [8] - The M2-M1 spread at the end of December 2025 was 4.7 percentage points, widening from the previous month's 3.1 percentage points [8] Investment Recommendations - The technology sector remains a long-term investment focus, benefiting from price increases in the supply chain, domestic substitution, and accelerated AI applications [8] - The consumer sector is expected to continue benefiting from policy support, with attention needed on policy implementation and improvements in consumption data [8] - Given the escalating geopolitical tensions, precious metals and other safe-haven assets are likely to benefit [8]

Market Overview - The Hong Kong stock market opened slightly lower on January 19, with the Hang Seng Index down 0.76% at 26,641.6 points, the Hang Seng Tech Index down 0.77% at 5,777.07 points, the State-Owned Enterprises Index down 0.76% at 9,151.07 points, and the Red Chip Index down 0.4% at 4,122.65 points [1] - Major tech stocks experienced declines, including Alibaba down 2.53%, Tencent down 0.65%, JD.com down 0.53%, Xiaomi down 1.29%, NetEase down 0.83%, Meituan down 1.2%, Kuaishou down 1.53%, and Bilibili down 2.69% [1] - The non-ferrous metals sector was active, with Zijin Mining rising over 3%, while the lithium battery sector saw most stocks increase, with BYD rising over 1% [1] - Some domestic property stocks fell, with Country Garden down over 10%, and the biopharmaceutical sector opened lower, with Tigermed down over 2% [1] Company News - China Shenhua (01088.HK) expects coal sales volume in 2025 to be 431 million tons, a year-on-year decrease of 6.4% [2] - New China Life Insurance (01336.HK) anticipates cumulative original insurance premium income in 2025 to reach 195.899 billion yuan, a year-on-year increase of 15% [3] - Yongjia Group (03322.HK) projects a revenue growth rate of approximately 16% for its high-end fashion retail business in the fourth quarter of 2025 [4] - Ronshine China (03301.HK) expects total contract sales in 2025 to be approximately 3.777 billion yuan, a year-on-year decrease of 50.96% [5] - Tianhong International Group (02678.HK) issued a profit warning, expecting a net profit increase of about 60% for the 2025 fiscal year due to a recovery in domestic and international market orders [5] - Qizhi Group (00917.HK) anticipates turning a profit in 2025, with net profit estimated between 270 million to 330 million yuan, compared to a loss of 1.663 billion yuan in the previous year [5] - October Rice Field (09676.HK) issued a profit warning, expecting adjusted net profit of approximately 550 million to 590 million yuan in 2025, a year-on-year increase of about 57.6% to 69.1% [5] - China Boton (03318.HK) issued a profit warning, expecting goodwill impairment losses of no less than approximately 750 million yuan for its tobacco flavor business in 2025 [5] Strategic Insights - Guojin Securities suggests that the Hong Kong stock market is entering a "spring market" at the beginning of 2026, likely to continue until mid-year, driven by domestic and international easing expectations and policy collaboration [9] - Galaxy Securities anticipates narrow fluctuations in the Hong Kong stock market due to reduced short-term interest rate cut expectations from the Federal Reserve and increased global geopolitical uncertainties [9] - GF Securities views the chemical industry as a typical cyclical sector, predicting a "dawn" phase for the chemical industry amid capital expenditure growth turning negative and a focus on domestic demand expansion [9]